Fig. 2

ACR50 response rate of control group, placebo + MTX (ie, MTX) across interventions and studies. A boxplot summary of the control group response rates, by intervention, is shown. Interventions associated with control group response rates above the average line may have unadjusted NMA results biased against them, while interventions with control group response rates below the average line may have unadjusted NMA results biased in their favor. Legend: ABA = abatacept; ABP501 = biosimilar adalimumab; ADA = adalimumab; ANBAI = AnBaiNuo (biosimilar adalimumab); BAR_4 = 4 mg baricitinib; CERTO = certolizumab pegol; csDMARD = conventional synthetic disease-modifying anti-rheumatic drug; CT-P13 = biosimilar of infliximab; ETN = etanercept; GOL = golimumab; HCQ = hydroxychloroquine; HD203 = etanercept biosimilar; INF = infliximab; IV = intravenous; MTX = methotrexate; RIT = rituximab; SAR_200 = 200 mg sarilumab; SB2 = biosimilar infliximab 3 mg/kg; SB4 = biosimilar etanercept 50 mg; SB5 = biosimilar adalimumab; SC = subcutaneous; SSZ = sulfasalazine; STD = standard dose; TOC_4 = tocilizumab 4 mg/kg; TOC_8 = 8 mg/kg tocilizumab; TOF = tofacitinib; ZRC-3197 = biosimilar of adalimumab